EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial

Sari Kytölä iD, Mika Kurkela, Johanna I Kiiski, Ida Vänttinen, Tanja Ruokoranta, Anu Partanen, Annasofia Holopainen, Marja Pyörälä, Milla E L Kuusisto, Timo Siitonen, Sirpa Koskela, Johanna Rimpiläinen und 5 weitere

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70041 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Sari Kytölä und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Helsinki University: iCAN - Digital Precision Medicine and HiLIFE, FiCAN South, Finnish Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax has improved outcomes for acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy. Managing cytopenias and infections remains challenging. Previous pharmacokinetic studies have shown considerable variability in venetoclax concentrations between individuals; however, data regarding whether higher levels increase toxicity or impact efficacy are limited. This study assessed the feasibility of using fingertip capillary blood plasma, collected via microsampling, to measure venetoclax trough concentrations and explored their association with toxicity and treatment outcomes. Concentrations were measured during the first two therapy cycles in 89 patients with newly diagnosed or relapsed or refractory AML receiving azacitidine and venetoclax. Validation with 37 parallel venipuncture and capillary samples showed excellent correlation ( R 2 of 0.835, p < 0.0001). No significant associations were found between venetoclax concentrations and patient characteristics such as gender, age and weight. While no statistically significant effects on therapy outcomes or adverse events were identified, trends suggested lower concentrations in refractory patients and higher in those with morphologic leukaemia free state or extended cycle length. Additionally, three separate CYP3A4 and CYP3A5 single‐nucleotide polymorphisms were analysed in 81 patients for their potential impact on venetoclax concentrations. This study demonstrates that the capillary blood plasma method is viable for measuring venetoclax levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesBridged Bicyclo Compounds, HeterocyclicAntineoplastic AgentsDrug MonitoringBlood Specimen CollectionHumansMaleFemaleAgedMiddle AgedAdultAged, 80 and overCytochrome P-450 CYP3APolymorphism, Single NucleotideTreatment OutcomeFeasibility StudiesCapillaries

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicAntineoplastic AgentsCytochrome P-450 CYP3ACYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
  • Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Cancer Center, Oulu University Hospital, Research Unit of Biomedicine and Internal Medicine, Oulu, Finland.
  • Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.

ORCID-Profile: Sari Kytölä, Mikko Niemi

Förderung

  • Helsinki University: iCAN - Digital Precision Medicine and HiLIFE
  • FiCAN South
  • Finnish Medical Foundation
  • Cancer Foundation Finland
  • Helsinki University Hospital Comprehensive Cancer Center
  • Suomen Lääketieteen Säätiö
  • Syöpäsäätiö

Zitieren

APA

Kytölä, S., Kurkela, M., Kiiski, J. I., Vänttinen, I., Ruokoranta, T., Partanen, A., Holopainen, A., Pyörälä, M., Kuusisto, M. E. L., Siitonen, T., Koskela, S., Rimpiläinen, J., Ettala, P., Kuusanmäki, H., Niemi, M., Backman, J. T., & Kontro, M. (2025). Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70041

Vancouver

Kytölä S, Kurkela M, Kiiski JI, Vänttinen I, Ruokoranta T, Partanen A, et al. Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70041

BibTeX
@article{Kytl2025,
  author = {Kytölä, Sari and Kurkela, Mika and Kiiski, Johanna I and Vänttinen, Ida and Ruokoranta, Tanja and Partanen, Anu and Holopainen, Annasofia and Pyörälä, Marja and Kuusisto, Milla E L and Siitonen, Timo and Koskela, Sirpa and Rimpiläinen, Johanna and Ettala, Pia and Kuusanmäki, Heikki and Niemi, Mikko and Backman, Janne T and Kontro, Mika},
  title = {Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70041}
}
Kostenlos starten →